Tesamorelin

Tesamorelin is a synthetic analogue of human growth-hormone-releasing hormone (GHRH): the full 44-amino-acid sequence with a trans-3-hexenoyl group added to the N-terminus, which protects it from enzymatic breakdown. It acts on the GHRH receptor.

Yes, as the active ingredient of a prescription medicine, approved by the FDA in 2010 for one specific use. That approval covers the finished medicine made under pharmaceutical manufacturing controls; the tesamorelin sold here is a research reagent, not a medicine.

Tesamorelin and sermorelin act on the growth-hormone-releasing hormone (GHRH) receptor; ipamorelin acts on a different receptor, the ghrelin receptor (GHS-R1a). Sermorelin is the 29-amino-acid active fragment of human GHRH. Tesamorelin is the full 44-amino-acid GHRH sequence with an added trans-3-hexenoyl group that stabilizes it. Ipamorelin is a much smaller synthetic pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2.

They are unrelated peptides with different targets. Retatrutide is a 39-amino-acid, fatty-acid-modified triple agonist of the GIP, GLP-1 and glucagon receptors, and is investigational. Tesamorelin is a 44-amino-acid analogue of growth-hormone-releasing hormone (GHRH) with an N-terminal trans-3-hexenoyl group; it acts on the GHRH receptor and is an FDA-approved active ingredient. Both are sold here as research reagents.

These peptides act on different receptors. Tesamorelin is a 44-amino-acid analogue of growth-hormone-releasing hormone (GHRH) that acts on the GHRH receptor. Tirzepatide is a 39-amino-acid, fatty-acid-modified agonist of the GIP and GLP-1 receptors. Both are FDA-approved active ingredients of prescription medicines; the material sold here, in either case, is a research reagent.

No. AOD 9604 is a 16-amino-acid peptide based on the C-terminal end of growth hormone and is not an approved medicine. Tesamorelin is a 44-amino-acid analogue of growth-hormone-releasing hormone (GHRH) that acts on the GHRH receptor, and it is an FDA-approved active ingredient. They differ in sequence, length and target; both are sold here as research reagents.

No. HGH is the 191-amino-acid growth hormone itself. Ipamorelin, GHRP-6, hexarelin, sermorelin, CJC-1295 and tesamorelin are much smaller synthetic peptides, called growth hormone secretagogues, that act on pituitary receptors controlling the body's own release of growth hormone: the ghrelin receptor (GHS-R1a) or the GHRH receptor. None of them contains the growth hormone sequence.

Tesamorelin has been studied as a stabilized GHRH receptor agonist. Preclinical work examined its binding to the receptor on pituitary cells and the growth hormone and IGF-1 axis in animal models. It went through human clinical trials, including trials in people with HIV-associated lipodystrophy, and became an FDA-approved active ingredient in 2010. Findings in cells or animals do not establish effects in people.

No. Tesamorelin is a 44-amino-acid synthetic peptide, an analogue of growth-hormone-releasing hormone (GHRH), the hypothalamic hormone that signals the pituitary through the GHRH receptor. Growth hormone (HGH) is a different and much larger molecule, a 191-amino-acid protein made by the pituitary. Tesamorelin contains none of the growth hormone sequence.

No. GLP-1 receptor agonists such as semaglutide act on the glucagon-like peptide-1 receptor. Tesamorelin acts on the GHRH receptor, and ipamorelin acts on the ghrelin receptor (GHS-R1a). They are unrelated in sequence and target, although all three are peptides and are sometimes discussed together online.

Both are synthetic GHRH analogues that act on the GHRH receptor, stabilized against enzymatic breakdown in different ways. Tesamorelin is the full 44-amino-acid GHRH sequence with a trans-3-hexenoyl group on the N-terminus. CJC-1295 is the shorter 29-residue fragment with four amino-acid substitutions; the DAC version adds a linker that bonds to albumin. Tesamorelin is an FDA-approved active ingredient; CJC-1295 has never been approved.

Because they act on two different receptors that both regulate growth hormone release from the pituitary. Tesamorelin is a GHRH analogue acting on the GHRH receptor; ipamorelin acts on the ghrelin receptor (GHS-R1a). Researchers studying how these two signaling pathways interact sometimes compare the compounds alone and together. No combination of the two is an approved product, and they are supplied here as separate vials.

Yes, for storage. Keep the sealed lyophilized vial refrigerated at 2–8 °C away from light, or frozen at −20 °C for long-term storage; short periods at room temperature, such as shipping, are tolerated. After reconstitution, keep the solution refrigerated, avoid freeze-thaw cycles and follow the stability window on the label and Certificate of Analysis.

Use the standard procedure for a lyophilized peptide. Let the vial reach room temperature, add sterile diluent slowly down the inside wall of the vial, and swirl gently until clear; do not shake. Concentration equals the labeled mass divided by the volume added, so a 10 mg vial dissolved in a given volume of diluent holds 10 mg divided by that volume per mL. Label the vial with the date and concentration and refrigerate it.

As a research reagent, tesamorelin costs more than short peptides because of its length and modification. A 44-amino-acid chain needs 44 coupling cycles in solid-phase synthesis, each with some yield loss, plus an added N-terminal trans-3-hexenoyl group, and the crude product needs extensive HPLC purification to remove closely related truncated sequences. Longer peptides therefore have lower yields and higher costs per milligram.

Sermorelin, CJC-1295 and tesamorelin are all GHRH analogues acting on the GHRH receptor: sermorelin is the native 29-amino-acid fragment, CJC-1295 (no DAC) is that fragment with four stabilizing substitutions, and tesamorelin is the full 44-residue sequence with an N-terminal hexenoyl group. The CJC-1295/ipamorelin blend adds a second compound, ipamorelin, which acts on a different receptor, the ghrelin receptor (GHS-R1a).

These belong to unrelated research areas. BPC-157 (a 15-amino-acid gastric-protein-derived peptide) and TB-500 (derived from the actin-binding protein thymosin β4) are studied in tissue-repair models. CJC-1295, sermorelin and tesamorelin are GHRH analogues acting on the GHRH receptor in the growth hormone axis. They share no sequence, receptor or pathway.

They act on different receptors. GHRP-6, GHRP-2 and hexarelin are small synthetic hexapeptides that act on the ghrelin receptor (GHS-R1a). CJC-1295, sermorelin and tesamorelin are much longer analogues of growth-hormone-releasing hormone, 29 to 44 amino acids, that act on the GHRH receptor. Both receptors are on pituitary cells and regulate growth hormone release through separate signaling pathways.

They sit at different points of the growth hormone axis. CJC-1295, sermorelin and tesamorelin (GHRH receptor) and ipamorelin, GHRP-6 and hexarelin (ghrelin receptor) are small peptides that act on pituitary receptors controlling growth hormone release. IGF-1 LR3 acts further downstream: it is an analogue of IGF-1, the hormone produced largely in response to growth hormone, and binds the IGF-1 receptor directly.

They are not in the same pathway. Follistatin is a binding protein that captures activin, myostatin and related TGF-β family ligands outside cells. IGF-1 LR3 acts on the IGF-1 receptor, and CJC-1295 and tesamorelin act on the GHRH receptor in the growth hormone axis. Follistatin is a large recombinant glycoprotein; CJC-1295 and tesamorelin are synthetic peptides.

Tesamorelin: molecular formula C221H366N72O67S; molecular weight 5135.9 g/mol; CAS number 218949-48-5. Sequence: trans-3-hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2. Match these identifiers against the Certificate of Analysis for the lot.

Yes. Each lot has its own Certificate of Analysis, linked on this page for the current lot of each size: 5mg (99.12% HPLC purity); 10mg (99.56% HPLC purity); 20mg (99.93% HPLC purity). Past certificates are archived in the COA library; contact us with the lot number on the vial label if a certificate is missing.

99.12% (HPLC, current lot). Purity is measured by high-performance liquid chromatography (HPLC) and reported on the lot's Certificate of Analysis.

Tesamorelin is supplied as lyophilized powder in a sealed vial in 3 sizes: 5mg, 10mg, 20mg. In stock and dispatched in 1–2 business days. Quantity pricing applies automatically at 5+ and 10+ vials of the same size.

Store sealed at −20 °C, dry and protected from light.